Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 3/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11166846 | 0.87 | DRD4 (0.38) | DRD4KMT2A | |
| SCHEMBL25791297 | 0.81 | DRD4 (0.36) | SLC6A2SLC6A4SIGMAR1DRD4HTR2A | |
| SCHEMBL11155397 | 0.78 | DRD4 (0.40) | DRD4KMT2A | |
| Hydrochloric Acid SCHEMBL29915606 | 0.76 | DRD4 (0.40) | DRD4 | |
| SCHEMBL25253616 | 0.75 | DRD4 (0.39) | TAAR1CYP2A6DRD4HTR2AKMT2A | |
| SCHEMBL9933973 | 0.74 | DRD4 (0.40) | DRD4KMT2A | |
| SCHEMBL24842084 | 0.74 | IDO1 (0.37) | DRD4 | |
| SCHEMBL24501603 | 0.73 | DRD4 (0.38) | SLC6A4DRD4HTR2AHTR2CKMT2A | |
| SCHEMBL24656020 | 0.73 | DRD4 (0.38) | DRD4KMT2A | |
| SCHEMBL17248114 | 0.72 | PDE4B (0.41) | ADORA2AADORA1DRD4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059184-A1 | IMIDAZOPYRIDINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2025-02-20 | — | — | US | disclosed |
| WO-2023114844-A1 | IMIDAZOPYRIDINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023114844-A1 | IMIDAZOPYRIDINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059184-A1 | IMIDAZOPYRIDINE PSYCHOPLASTOGENS AND USES THEREOF | GRIN2A, GAP43, GRIN2C | SLC6A2 361/4885TAAR1 682/4885MAOA 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.